MD Biosciences is proud to announce the launch of Salspera, LLC (www.salspera.com) to advance Saltikva® (MDB401B), a microbial-based immunotherapeutic product targeting cancer, towards regulatory approval. The Salspera team is actively preparing the next clinical study phase following the successful completion of Phase 1 human safety studies. Saltikva® has been presented at high level meetings, including the most recent conference held at the NIH National Cancer Institute. Next generation programs are also advancing through the preclinical pipeline, with the goal of providing a robust palette of specialized attenuated Salmonella-based guided therapies addressing patient needs with personalized “cocktails” and adjunct therapies.
About MD Biosciences
MD Biosciences is a research and development company founded in 1991 with four business divisions. MD Biosciences CLIA laboratory provides assay development and clinical testing services for clinical stage programs. MD Biosciences Preclinical Services provide contract research services for drug development in areas including immuno-oncology, CNS, inflammatory and metabolic diseases. Early stage compounds in the area of neuropathic pain and cancer are being developed through MD Biosciences Innovalora Ltd. Finally, MD Biosciences is a manufacturer and distributor of proprietary products for industrial and academic drug discovery laboratories.